Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is dermatofibrosarcoma protuberans (dfsp)?
Dermatofibrosarcoma protuberans, or DFSP, is a rare cancer that begins in the deep layer of the skin (the dermis) and is classified as a soft-tissue sarcoma of the skin. It usually appears as a slow-growing, firm patch or lump — often on the trunk, shoulders, or limbs — that may start as a small, painless area resembling a scar or a bruise and gradually thickens and rises over months or years (the name 'protuberans' refers to the way it eventually bulges outward). Because it grows so slowly, it is often present for a long time before it is diagnosed. The defining behavior of DFSP is the key to understanding it: it is locally aggressive but almost never spreads to other parts of the body. The cancer sends out finger-like, root-like extensions that creep outward through the skin well beyond what can be seen or felt, which is why it has a strong tendency to come back after removal if those hidden extensions are not fully cleared. Distant spread to the lungs or other organs is very rare and happens mainly with an uncommon, more aggressive variant. DFSP is driven by a specific, characteristic genetic change in the tumor cells (a rearrangement involving the PDGFB gene), which is important because it both helps confirm the diagnosis under the microscope and provides a target for a medication used in difficult cases. The cornerstone of treatment is surgery that removes the tumor along with a wide margin or with careful microscopic checking of the edges to catch those hidden roots. Radiation and a targeted oral drug are valuable additions for tumors that are hard to remove completely, that come back, or that are too extensive for surgery alone.
The main types
Doctors group dermatofibrosarcoma protuberans (dfsp) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Classic DFSP | The usual slow-growing form — a firm skin plaque or nodule that is locally invasive but does not spread to distant organs; cured by complete removal. |
| Pigmented DFSP (Bednar tumor) | A variant that contains brown pigment; behaves like classic DFSP and is treated the same way. |
| Fibrosarcomatous DFSP (FS-DFSP) | An uncommon, more aggressive form in which part of the tumor takes on a higher-grade pattern; this variant carries a higher risk of recurrence and the small possibility of distant spread, so it is watched more closely. |
| Recurrent DFSP | A tumor that has come back after prior removal, usually because hidden root-like extensions were not fully cleared; treated with wider re-excision and often radiation. |
Staging, in plain terms
DFSP can technically be described using the staging framework for soft-tissue sarcomas, which considers the size of the tumor, how deep it goes, its grade (how aggressive the cells look under the microscope), and whether it has spread to lymph nodes or distant organs. In practice, however, formal staging plays a smaller role than it does for most cancers, because DFSP almost never spreads. The real questions that drive treatment are local ones: how far the tumor and its hidden, root-like extensions reach through the skin, and whether they can be completely removed. That is why so much attention goes to obtaining clear surgical margins. The grade matters mainly for spotting the uncommon fibrosarcomatous variant, in which part of the tumor becomes higher-grade; that variant carries a higher chance of coming back and the small possibility of spreading to the lungs, so it is followed more closely and may prompt imaging to check for distant disease. For typical DFSP, by contrast, distant imaging is usually unnecessary. The diagnosis is confirmed with a biopsy, and identifying the characteristic genetic change in the tumor not only secures the diagnosis but also indicates whether the targeted oral drug could help if surgery alone cannot control the tumor. In short, DFSP is managed less by a stage number and more by completely removing the tumor and its hidden extensions, with extra vigilance reserved for the rare aggressive variant.
| Soft-tissue sarcoma framework (size, depth, grade) — but managed mainly by complete removal because distant spread is rare | What it generally means |
|---|---|
| Localized, resectable | A tumor confined to the skin and underlying tissue that can be completely removed; wide surgery or margin-controlled excision is usually curative. |
| Locally advanced or recurrent | A larger tumor, one in a location where wide removal is difficult (such as the head and neck), or one that has come back; treated with re-excision plus radiation, and sometimes the targeted oral drug to shrink it first. |
| Fibrosarcomatous variant | A tumor containing a higher-grade component, carrying more risk of recurrence and a small chance of distant spread; treated thoroughly with surgery and often radiation, with imaging to check for spread. |
| Metastatic (very rare) | The uncommon situation, almost always with the fibrosarcomatous variant, where the cancer spreads to the lungs; treated with the targeted oral drug and a coordinated specialist plan. |
The standard of care
Dermatofibrosarcoma Protuberans (DFSP) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Wide local excision
Surgery that removes the tumor with a generous margin of healthy tissue to capture its hidden root-like extensions; the main curative treatment for most DFSP.
Mohs or margin-controlled surgery
A technique that checks the edges of the removed tissue under the microscope (sometimes in stages) to confirm all the hidden extensions are cleared while sparing as much normal tissue as possible — especially useful on the face and other cosmetically sensitive areas.
Radiation therapy
Used after surgery when the edges are close or involved and re-excision isn't feasible, or as the main treatment for tumors that can't be removed — it substantially lowers the chance of recurrence.
Targeted oral therapy (imatinib)
A pill that blocks the very pathway driven by DFSP's characteristic genetic change; it can shrink large or recurrent tumors before surgery and is the main treatment for the rare cases that spread.
Long-term follow-up
Because DFSP can recur years later, regular skin exams of the treated area are important to catch any return early, when it is easiest to treat.
How radiation treatment works
Radiation therapy treats DFSP by delivering focused beams of energy that damage the DNA inside the tumor cells, so they lose the ability to grow and divide. The role of radiation in this cancer follows directly from how DFSP behaves. Its defining trait is that it sends out hidden, root-like extensions far beyond the visible edge of the tumor, which is why it tends to recur locally if those extensions are not completely removed — and why radiation, which can treat a wide area including microscopic disease, is such a useful partner to surgery. The most common use is after an operation: when the surgeon removes the tumor but the edges come back close to or involved by cancer and further surgery isn't practical, radiation to the surgical area treats any microscopic tumor cells left behind and substantially lowers the chance the cancer comes back. Radiation can also be the primary treatment for a tumor that cannot be removed because of its size or location, and it can be given before surgery to shrink a large tumor so that a complete, less disfiguring removal becomes possible. Because DFSP almost never spreads to distant organs, the goal of radiation is local control — eradicating the disease in and around the original site — rather than treating the whole body. Modern techniques such as intensity-modulated radiation shape the dose tightly around the target, protecting the surrounding skin and nearby structures, which matters when the tumor sits in a cosmetically or functionally important area. Used thoughtfully alongside specialized surgery, radiation makes durable local control achievable even for difficult, recurrent, or hard-to-remove tumors. For the small number of tumors driven by DFSP's characteristic genetic change that cannot be controlled with surgery and radiation, a targeted oral drug provides an additional, biology-based option.
The main ways radiation is delivered for dermatofibrosarcoma protuberans (dfsp):
Postoperative (adjuvant) radiation
Radiation to the surgical area after removal, used when the margins are close or positive and further surgery isn't practical, treats any microscopic tumor left behind and sharply reduces the chance of recurrence.
Definitive radiation
For a tumor that cannot be removed — for example, because of its size or location — focused external-beam radiation can serve as the primary treatment to control the disease.
Preoperative radiation in selected cases
Radiation given before surgery can shrink a large tumor and make a complete, less disfiguring removal more achievable.
Intensity-modulated radiation (IMRT)
Shaping the radiation beams tightly around the target protects surrounding skin and structures, useful when the tumor is near cosmetically or functionally important areas.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Margin-controlled surgery achieves very high cure rates: Studies of Mohs and margin-controlled excision for DFSP report local recurrence rates of only a few percent, confirming that completely clearing the tumor's hidden extensions is the key to cure while sparing healthy tissue.[1]
DFSP margin-controlled surgery series
Radiation lowers recurrence when margins are close or positive: Adding radiation after surgery for DFSP with close or involved margins, or using it for unresectable tumors, markedly improves local control, supporting its role when complete surgical clearance cannot be achieved.[2]
DFSP adjuvant radiotherapy studies
Targeted therapy works against DFSP's driver gene: Because DFSP is driven by a characteristic genetic rearrangement, the targeted drug imatinib can shrink large, recurrent, or metastatic tumors, providing an effective biology-based option when surgery and radiation are not enough.[3]
Imatinib in DFSP trials
Common questions
Is DFSP a dangerous cancer? DFSP is a true cancer, but a relatively favorable one because it almost never spreads to other parts of the body. Its main challenge is local: it sends out hidden root-like extensions and can come back where it started if those aren't completely removed. With complete removal, the great majority of people are cured. An uncommon, more aggressive variant carries a small risk of spreading and is watched more closely.
Why does it tend to come back, and how is that prevented? DFSP grows outward in thin, root-like extensions that reach well beyond the visible tumor, so a recurrence happens when some of those hidden roots are left behind. Prevention comes from surgery that removes the tumor with a wide margin or with careful microscopic checking of the edges, and from adding radiation when the margins are close or involved and further surgery isn't feasible.
When is radiation or the targeted pill used instead of just surgery? Surgery is the main treatment and cures most DFSP. Radiation is added when the surgical edges are close or involved and re-excision isn't practical, or used as the primary treatment for tumors that can't be removed. The targeted oral drug (imatinib), which blocks DFSP's driver gene, is used to shrink large or recurrent tumors before surgery and to treat the rare cases that spread.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.